利用临床数据来提高对儿童塞夫特里亚克松人口药动力学模型的性能评估
Stef Schouwenburg1,2, Tim Preijers3,4, Alan Abdulla3,4
1Department of Hospital Pharmacy, Erasmus University Medical Centre, Postal Box 2040, 3000 CA, Rotterdam, The Netherlands. s.schouwenburg@erasmusmc.nl.
在儿科重症监护病房 (PICU) 中对 ceftriaxone 群体药动力学 (popPK) 模型的外部验证显示,性能不足. 目前的剂量可能需要重新评估,以防止毒性并优化危急儿童的治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 儿科重症监护中心儿童重症监护中心
- 抗生素剂量 抗生素剂量
背景情况:
- 败血症在儿科重症监护室 (PICU) 很常见.
- 塞夫特里亚克松是一种经常用于治疗儿科感染的抗生素.
- 有限的数据存在于儿童中塞夫特里亚克森的群体药理动力学 (popPK).
研究的目的:
- 为了对儿科ICU患者的现有 ceftriaxone popPK模型进行外部验证.
- 评估这些模型是否适用于个性化剂量.
- 为了确定这个群体中表现最好的模型.
主要方法:
- 利用了前性EXPAT Kids PK/PD研究中的数据.
- 使用NONMEM软件实现和评估模型.
- 通过适合性和视觉预测检查评估模型准确性.
- 使用错误指标 (RPE,RMSE,MAPE) 评估预测性能.
主要成果:
- 在评估的模型中,预测性能的显著变化.
- 模型通常预测过高的塞夫特里亚克森度.
- 未结合的塞夫特里亚克森popPK模型显示性能不足.
- 没有一个模型达到所有预定义的准确性和精度值.
结论:
- 外部数据集显示了高氏的最低度,这表明了潜在的过量剂量.
- 目前的塞夫特里亚剂量方案可能需要重新评估,以最大限度地降低毒性.
- 未来的研究应该专注于优化氏的剂量,特别是脑膜炎,平衡暴露和低谷度.
- 对popPK模型的外部评估对PICU人群至关重要.
更多相关视频
06:51Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
Published on: December 10, 2016
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
相关概念视频
Analysis of Population Pharmacokinetic Data
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
Factors Affecting Drug Response: Overview
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Model Approaches for Pharmacokinetic Data: Physiological Models
